519 related articles for article (PubMed ID: 20053190)
41. Combination systemic therapy for advanced renal cell carcinoma.
Miller RE; Larkin JM
Oncologist; 2009 Dec; 14(12):1218-24. PubMed ID: 19939892
[TBL] [Abstract][Full Text] [Related]
42. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
43. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
44. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
Shuuin T; Karashima H
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
[TBL] [Abstract][Full Text] [Related]
45. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
46. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
47. Management of mTOR inhibitor side effects.
Creel PA
Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
[TBL] [Abstract][Full Text] [Related]
48. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
[TBL] [Abstract][Full Text] [Related]
49. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
50. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
Bellmunt J; Eisen T; Szczylik C; Mulders P; Porta C
BJU Int; 2011 Apr; 107(8):1190-9. PubMed ID: 21078050
[TBL] [Abstract][Full Text] [Related]
51. Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.
Vano YA; Tartour E; Fournier LS; Beuselinck B; Mejean A; Oudard S
Expert Rev Anticancer Ther; 2014 May; 14(5):523-42. PubMed ID: 24640949
[TBL] [Abstract][Full Text] [Related]
52. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
[TBL] [Abstract][Full Text] [Related]
53. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
Agarwala SS; Case S
Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
[TBL] [Abstract][Full Text] [Related]
54. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
55. Non-clear cell advanced kidney cancer: is there a gold standard?
Sánchez P; Calvo E; Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
[TBL] [Abstract][Full Text] [Related]
56. mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
Eimer C; Gerullis H; Heuck C; Otto T
Anticancer Drugs; 2011 Jan; 22(1):18-23. PubMed ID: 21037468
[TBL] [Abstract][Full Text] [Related]
57. Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.
Felici A; Bria E; Tortora G; Cognetti F; Milella M
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1545-57. PubMed ID: 23253221
[TBL] [Abstract][Full Text] [Related]
58. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.
Rini BI
Clin Cancer Res; 2010 Mar; 16(5):1348-54. PubMed ID: 20179240
[TBL] [Abstract][Full Text] [Related]
59. Current management of advanced and metastatic renal cell carcinoma.
Ather MH; Masood N; Siddiqui T
Urol J; 2010; 7(1):1-9. PubMed ID: 20209445
[TBL] [Abstract][Full Text] [Related]
60. Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE; Figlin RA
Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
